|
1
|
Lyman GH, Giuliano AE, Somerfield MR,
Benson AB III, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS III,
Edge SB, Galper S, et al: American society of clinical oncology
guideline recommendations for sentinel lymph node biopsy in
early-stage breast cancer. J Clin Oncol. 23:7703–7720. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Veronesi U, Paganelli G, Viale G, Luini A,
Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti
G, et al: Sentinel-lymph-node biopsy as a staging procedure in
breast cancer: Update of a randomised controlled study. Lancet
Oncol. 7:983–990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lyman GH, Temin S, Edge SB, Newman LA,
Turner RR, Weaver DL, Benson AB III, Bosserman LD, Burstein HJ,
Cody H III, et al: Sentinel lymph node biopsy for patients with
early-stage breast cancer: American society of clinical oncology
clinical practice guideline update. J Clin Oncol. 32:1365–1383.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsujimoto M, Nakabayashi K, Yoshidome K,
Kaneko T, Iwase T, Akiyama F, Kato Y, Tsuda H, Ueda S, Sato K, et
al: One-step nucleic acid amplification for intraoperative
detection of lymph node metastasis in breast cancer patients. Clin
Cancer Res. 13:4807–4816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tamaki Y: One-step nucleic acid
amplification assay (OSNA) for sentinel lymph node biopsy. Breast
Cancer. 22:230–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rubio IT, Espinosa-Bravo M, Rodrigo M,
Amparo Viguri Diaz M, Hardisson D, Sagasta A, Dueñas B and Peg V:
Nomogram including the total tumoral load in the sentinel nodes
assessed by one-step nucleic acid amplification as a new factor for
predicting nonsentinel lymph node metastasis in breast cancer
patients. Breast Cancer Res Treat. 147:371–380. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teramoto A, Shimazu K, Naoi Y, Shimomura
A, Shimoda M, Kagara N, Maruyama N, Kim SJ, Yoshidome K, Tsujimoto
M, et al: One-step nucleic acid amplification assay for
intraoperative prediction of non-sentinel lymph node metastasis in
breast cancer patients with sentinel lymph node metastasis. Breast.
23:579–585. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shimazu K, Sato N, Ogiya A, Sota Y,
Yotsumoto D, Ishikawa T, Nakamura S, Kinoshita T, Tsuda H, Ohi Y,
et al: Intraoperative nomograms, based on one-step nucleic acid
amplification, for prediction of non-sentinel node metastasis and
four or more axillary node metastases in breast cancer patients
with sentinel node metastasis. Ann Surg Oncol. 25:2603–2611. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peg V, Espinosa-Bravo M, Vieites B,
Vilardell F, Antúnez JR, de Salas MS, Delgado-Sánchez JJ, Pinto W,
Gozalbo F, Petit A, et al: Intraoperative molecular analysis of
total tumor load in sentinel lymph node: A new predictor of
axillary status in early breast cancer patients. Breast Cancer Res
Treat. 139:87–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park SY, Kwon HJ, Choi Y, Lee HE, Kim SW,
Kim JH, Kim IA, Jung N, Cho NY and Kang GH: Distinct patterns of
promoter CpG island methylation of breast cancer subtypes are
associated with stem cell phenotypes. Mod Pathol. 25:185–196. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamamoto N, Nakayama T, Kajita M, Miyake
T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y and Noguchi S:
Detection of aberrant promoter methylation of GSTP1, RASSF1A, and
RARβ2 in serum DNA of patients with breast cancer by a newly
established one-step methylation-specific PCR assay. Breast Cancer
Res Treat. 132:165–173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abe M, Kagara N, Miyake T, Tanei T, Naoi
Y, Shimoda M, Shimazu K, Kim SJ and Noguchi S: Highly sensitive
detection of sentinel lymph node metastasis of breast cancer by
digital PCR for RASSF1A methylation. Oncol Rep. 42:2382–2389.
2019.PubMed/NCBI
|
|
13
|
Eads CA, Lord RV, Kurumboor SK,
Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR,
Danenberg KD, Danenberg PV, et al: Fields of aberrant CpG island
hypermethylation in Barrett's esophagus and associated
adenocarcinoma.pdf. cancer Res. 60:5021–5026. 2000.PubMed/NCBI
|
|
14
|
Ogino S, Kawasaki T, Brahmandam M, Cantor
M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ,
Laird PW, Loda M and Fuchs CS: Precision and performance
characteristics of bisulfite conversion and real-time PCR
(MethyLight) for quantitative DNA methylation analysis. J Mol
Diagn. 8:209–217. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW,
Kim JH, Kim IA, Jung N, Cho NY and Kang GH: Promoter CpG island
hypermethylation during breast cancer progression. Virchows Arch.
458:73–84. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morimoto K, Kim SJ, Tanei T, Shimazu K,
Tanji Y, Taguchi T, Tamaki Y, Terada N and Noguchi S: Stem cell
marker aldehyde dehydrogenase 1-positive breast cancers are
characterized by negative estrogen receptor, positive human
epidermal growth factor receptor type 2, and high Ki67 expression.
Cancer Sci. 100:1062–1068. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vilardell F, Novell A, Martin J, Santacana
M, Velasco A, Díez-Castro MJ, Cuevas D, Panadés MJ, González S,
Llombart A, et al: Importance of assessing CK19 immunostaining in
core biopsies in patients subjected to sentinel node study by OSNA.
Virchows Arch. 460:569–575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alvarenga CA, Paravidino PI, Alvarenga M,
Dufloth R, Gomes M, Zeferino LC and Schmitt F: Expression of CK19
in invasive breast carcinomas of special histological types:
Implications for the use of one-step nucleic acid amplification. J
Clin Pathol. 64:493–497. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parikh RR, Yang Q, Higgins SA and Haffty
BG: Outcomes in young women with breast cancer of triple-negative
phenotype: the prognostic significance of CK19 expression. Int J
Radiat Oncol Biol Phys. 70:35–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Willipinski-Stapelfeldt B, Riethdorf S,
Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J and Pantel K:
Changes in cytoskeletal protein composition indicative of an
epithelial-mesenchymal transition in human micrometastatic and
primary breast carcinoma cells. Clin Cancer Res. 11:8006–8014.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abd El-Rehim DM, Pinder SE, Paish CE, Bell
J, Blamey RW, Robertson JF, Nicholson RI and Ellis IO: Expression
of luminal and basal cytokeratins in human breast carcinoma. J
Pathol. 203:661–671. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chu PG and Weiss LM: Keratin expression in
human tissues and neoplasms. Histopathology. 40:403–439. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gupta V, Agarwal P and Deshpande P: Impact
of RASSF1A gene methylation on clinico-pathological features of
tumor and non-tumor tissue of breast cancer. Ann Diagn Pathol.
52:1517222021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moelans CB, de Groot JS, Pan X, van der
Wall E and van Diest PJ: Clonal intratumor heterogeneity of
promoter hypermethylation in breast cancer by MS-MLPA. Mod Pathol.
27:869–874. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nik-Zainal S, Davies H, Staaf J,
Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB,
Martin S, Wedge DC, et al: Landscape of somatic mutations in 560
breast cancer whole-genome sequences. Nature. 534:47–54. 2016.
View Article : Google Scholar : PubMed/NCBI
|
